ACN Newswire
HONG KONG, July 4, 2025 – (ACN Newswire) – Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company’s progress in building a fully integrated and independently operated mRNA platform and highlighted significant breakthroughs across several pipeline programs in cancer and autoimmune diseases.These achievements not only mark the accelerated implementation of Everest Medicines’ “dual-engine” strategy…
Read More
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation
Lawanda Klemp
18:20
HONG KONG, July 4, 2025 – (ACN Newswire) – Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company’s progress in building a fully integrated and independently operated mRNA platform and highlighted significant breakthroughs across several pipeline programs in
